You know, I thought the same. All the FUD about blood tests and these guys actually have reasonable initial blood test data - not that it will work for pre-cancerous lesions.
From the reading it almost seems that they just ran the plasma samples as part of proof of concept and that they'll move toward expansion of stool based applications for early detection.
Subesquently using these tissue biomarker panels ...on more than 300 normal and cancerous tissue samples, the researchers were able to accurately predict the type of cancer with an accuracy of 88%. Meanwhile testing the plasma biomarker panel on 42 independent plasma samples yielded an accuracy of 74% in distinguishing colorectal from pancreatic tumors.
"most of the error in that came from the sensitivity rather than specificity, meaning we missed a few of the cancers, probably due to sub-optimal sample conditions. We think probably with larger blood volumes that we collect on our own, we'll do better, as the samples we used for this were convenient; they were not collected according to our specifications...."
From a group of around 100 markers they used bioinformatics approaches to home in on a three marker panel for the unifersal detection of GI neoplasms with 95% accuracy; 2 markers to distinguish between upper and lower GI cancers and lower cancers with 94% accuracy. In addition they identified a 2 marker plasma based panel that was 78% accurate in assigning patients to cancer or control groups and 83% accurate in assigning cancer origin to colorectal or pancreatic sites.
Accurate site prediction of gastrointestinal cancer by novel methylated DNA markers: Discovery & validation
Purpose: Methylated DNA markers can discriminate upper from lower GI neoplasms (Gastroenterology 2013;144(5):S84). It is unknown if organ-specific molecular prediction of GI tumor site can be achieved.
Results: From the top 100 markers, 95 were validated and used for rPart modeling. A 3- marker panel (chr12.133484978-5047, BMP3, chr11.123301058-255) was selected for the universal detection of GI neoplasms, as it classified neoplasms and control tissues with 95% accuracy. Two markers (chr7.25896389-501, QKI) then assigned lower vs upper GI neoplasms with 94% accuracy. Finally, 3 markers (PDGFD, ELOVL2, PCBP3) called pancreaticobiliary vs gastroesophageal neoplasms with 94% accuracy. All 8 markers applied in a single model (Table) accurately predicted control vs tumor by site [88% (p
he meant ~ one MT/million. While I'd like to see these guys succeed it's hardly anything to get excited about. The only thing that will save their hinnies is PLA blending. The ONLY action to focus on is in single use hospital items and fibers. imho.
Look for the /r/Solazyme - it's what's called a subreddit. there is a sign up process but it's no big deal. solazyme_investor runs the subr and deftly moderates.